Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Development and validation of a method for the simultaneous quantification of endogenous steroids metabolized by CYP3A.

Translational and clinical pharmacology

Lee Y, Chae W, Yoon S, Chung JY, Cho JY.
PMID: 32656158
Transl Clin Pharmacol. 2020 Jun;28(2):73-82. doi: 10.12793/tcp.2020.28.e10. Epub 2020 Jun 24.

Cytochrome P450 (CYP) 3A enzymes, the most important phase 1 drug-metabolizing enzymes, are responsible for 50% of the metabolism of clinically used drugs. CYP3A activity varies widely among individuals, which can affect the probability of adverse drug reactions and...

Cite
Lee Y, Chae W, Yoon S, et al. Development and validation of a method for the simultaneous quantification of endogenous steroids metabolized by CYP3A. Transl Clin Pharmacol. 2020;28(2):73-82doi: 10.12793/tcp.2020.28.e10.
Lee, Y., Chae, W., Yoon, S., Chung, J. Y., & Cho, J. Y. (2020). Development and validation of a method for the simultaneous quantification of endogenous steroids metabolized by CYP3A. Translational and clinical pharmacology, 28(2), 73-82. https://doi.org/10.12793/tcp.2020.28.e10
Lee, Yujin, et al. "Development and validation of a method for the simultaneous quantification of endogenous steroids metabolized by CYP3A." Translational and clinical pharmacology vol. 28,2 (2020): 73-82. doi: https://doi.org/10.12793/tcp.2020.28.e10
Lee Y, Chae W, Yoon S, Chung JY, Cho JY. Development and validation of a method for the simultaneous quantification of endogenous steroids metabolized by CYP3A. Transl Clin Pharmacol. 2020 Jun;28(2):73-82. doi: 10.12793/tcp.2020.28.e10. Epub 2020 Jun 24. PMID: 32656158; PMCID: PMC7327190.
Copy Download .nbib Format: NLM
Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case-control study.

Pharmacogenomics and personalized medicine

Al-Eitan LN, Al-Dalalah IM, Mustafa MM, Alghamdi MA, Elshammari AK, Khreisat WH, Al-Quasmi MN, Aljamal HA.
PMID: 31564953
Pharmgenomics Pers Med. 2019 Sep 04;12:225-233. doi: 10.2147/PGPM.S212433. eCollection 2019.

BACKGROUND: A total of 50 million persons were diagnosed worldwide with epilepsy. One-third of them are experiencing debilitating seizures despite optimum anti-epileptic drugs (AEDs) treatment. Several studies have suggested that CYP3A5, CHRM2, and ZNF498 influence the pharmacokinetics of AEDs....

Cite
Al-Eitan LN, Al-Dalalah IM, Mustafa MM, et al. Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case-control study. Pharmgenomics Pers Med. 2019;12:225-233doi: 10.2147/PGPM.S212433.
Al-Eitan, L. N., Al-Dalalah, I. M., Mustafa, M. M., Alghamdi, M. A., Elshammari, A. K., Khreisat, W. H., Al-Quasmi, M. N., & Aljamal, H. A. (2019). Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case-control study. Pharmacogenomics and personalized medicine, 12225-233. https://doi.org/10.2147/PGPM.S212433
Al-Eitan, Laith N, et al. "Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case-control study." Pharmacogenomics and personalized medicine vol. 12 (2019): 225-233. doi: https://doi.org/10.2147/PGPM.S212433
Al-Eitan LN, Al-Dalalah IM, Mustafa MM, Alghamdi MA, Elshammari AK, Khreisat WH, Al-Quasmi MN, Aljamal HA. Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case-control study. Pharmgenomics Pers Med. 2019 Sep 04;12:225-233. doi: 10.2147/PGPM.S212433. eCollection 2019. PMID: 31564953; PMCID: PMC6732506.
Copy Download .nbib Format: NLM
[No title available]

Annals of translational medicine

Qiao EQ, Yang HJ, Yu XF, Gong LJ, Zhang XP, Chen DB.
PMID: 34733941
Ann Transl Med. 2021 Sep;9(17):1389. doi: 10.21037/atm-21-4199.

BACKGROUND: Triple-negative breast cancer (TNBC) is characterized by its aggressiveness and poor prognosis. Docetaxel is the common chemotherapeutic drug used in the treatment of TNBC. However, resistance to docetaxel has limited the effectiveness of TNBC treatment. Petroleum ether extracts...

Cite
Qiao EQ, Yang HJ, Yu XF, et al. . Ann Transl Med. 2021;9(17):1389doi: 10.21037/atm-21-4199.
Qiao, E. Q., Yang, H. J., Yu, X. F., Gong, L. J., Zhang, X. P., & Chen, D. B. (2021). . Annals of translational medicine, 9(17), 1389. https://doi.org/10.21037/atm-21-4199
Qiao, En-Qi, et al. "." Annals of translational medicine vol. 9,17 (2021): 1389. doi: https://doi.org/10.21037/atm-21-4199
Qiao EQ, Yang HJ, Yu XF, Gong LJ, Zhang XP, Chen DB. . Ann Transl Med. 2021 Sep;9(17):1389. doi: 10.21037/atm-21-4199. PMID: 34733941; PMCID: PMC8506551.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries